|
Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis |
Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmology 2014; 132(11): 1317-1326 Indexing Status Subject indexing assigned by NLM MeSH Angiogenesis Inhibitors /adverse effects; Antibodies, Monoclonal, Humanized /adverse effects; Bevacizumab; Cardiovascular Diseases /chemically induced; Hemorrhage /chemically induced; Humans; Intravitreal Injections; Macular Degeneration /drug therapy; Macular Edema /drug therapy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Vein Occlusion /drug therapy; Risk Factors; Vascular Endothelial Growth Factor A /antagonists & inhibitors AccessionNumber 12014046758 Date bibliographic record published 04/11/2014 |
|
|
|